March 29, 2018Press Releases
AUSTIN, Texas, March 29, 2018 /PRNewswire/ — Genprex, Inc., a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today the pricing of its initial public offering on March 28, 2018 of an aggregate of 1,280,000 shares of common stock at a public offering price of $5.00 per share, before underwriting discounts. The Company has also granted […]
